EXHIBIT 10.67

                                       =========================================
                                       ***TEXT OMITTED AND FILED SEPARATELY
                                           CONFIDENTIAL TREATMENT REQUESTED
                                            UNDER 17 C.F.R. SS.SS.200.80(B)(4),
                                                 200.83 AND 240.24B-2
                                       =========================================

                                LICENSE AGREEMENT

          THIS LICENSE AGREEMENT (the "Agreement") is made as of July 22, 1998
(the "Effective Date") by and between CORVAS INTERNATIONAL, INC., a Delaware
corporation ("CORVAS"), and ORTHO-CLINICAL DIAGNOSTICS, INC., a New York
corporation and a wholly-owned subsidiary of Johnson & Johnson ("OCD").

          WHEREAS, CORVAS and Ortho Diagnostic Systems, Inc., a predecessor of
OCD ("ODSI") have entered into that certain License Agreement dated as of June
8, 1992 (the "License Agreement"), pursuant to which CORVAS granted to ODSI
licenses to certain patent rights held by CORVAS for the development and
commercialization of certain IN-VITRO diagnostic assay products incorporating
recombinant human tissue factor;

          WHEREAS, CORVAS and OCD wish to terminate the License Agreement; and

          WHEREAS, CORVAS wishes to grant to OCD, and OCD wishes to obtain from
CORVAS, an exclusive license under certain patent rights held by CORVAS for the
development and commercialization of certain IN-VITRO diagnostic assay products
based on or incorporating recombinant human tissue factor on the terms and
subject to the conditions set forth herein.

          Now, THEREFORE, in consideration of the mutual covenants and promises
hereinafter set forth, the parties hereto hereby agree as follows:

                                    ARTICLE I
                                   DEFINITIONS

          1.1   "AFFILIATE" means an individual, trust, business trust, joint
venture, partnership, corporation, association or any other entity which owns,
is owned by or is under common ownership with a party. For the purposes of this
definition, the term "owns" (including, with correlative meanings, the terms
"owned by" and "under common ownership with") as used with respect to any party,
shall mean the possession (directly or indirectly) of 50% or more of the
outstanding voting securities of a corporation or comparable equity interest in
any other type of entity.

          1.2   "COMMERCIAL PURPOSE" means the transfer or use of any Product
for valuable consideration.

          1.3   "CONFIDENTIAL INFORMATION" means any confidential or proprietary
information, including, without limitation, information related to the CORVAS
Patent Rights or the existence of, terms of, or performance of, this agreement,
whether in oral, written, graphic or electronic form.

          1.4   "CONTROL" means possession of the ability to grant a license or
sublicense as provided for herein without violating the terms of any agreement
or other arrangement with any Third Party.

<PAGE>

          1.5   "CORVAS PATENT RIGHTS" means all rights under the patents and/or
patent applications set forth on Exhibit A hereto, and any and all patents
issuing thereon, owned by or under the Control Of CORVAS, including, without
limitation, any and all substitutions, extensions (including supplemental
protection certificates), registrations, confirmations, reissues, divisionals,
continuations, continuations-in-part, re-examinations, renewals and foreign
counterparts of the aforementioned.

          1.6   "MULTI-TEST AUTOMATED PT PRODUCT" means any Product which is not
a Single-Test PT Product.

          1.7   "OCD-SCRIPPS LICENSE AGREEMENT" means any license agreement
between OCD and Scripps that comprises the patent rights embraced by the Scripps
License Agreement.

          1.8   "PRODUCT" means any IN-VITRO diagnostic assay product
(including, without limitation, Multi-Test Automated PT Products and Single-Test
PT Products), the manufacture, use or sale, offer to sell or import of which
would infringe a Valid Claim but for the license granted herein.

          1.9   "SCRIPPS LICENSE AGREEMENT" means that certain Research and
License Agreement for Human Tissue Factor for Diagnostic Purposes between CORVAS
and Scripps Clinic and Research Foundation dated as of May 19, 1988, as amended,
as set forth in Exhibit B hereto.

          1.10  "SINGLE-TEST PT PRODUCT" means any Product which is marketed,
sold or distributed through (a) retail outlets, whether supplied directly or
through drug wholesalers, including drug stores, food stores, combination food
and drug stores and mass merchandisers; (b) direct marketing, including sales by
mail-order catalog, telemarketing or television marketing; (c) facilities for
use in on-site, non-laboratory medical testing as part of an overall employee
wellness program; or (d) physicians' offices (which do not have an on-site group
practice laboratory) and physicians for distribution to their patients for
self-testing.

          1.11  "TERM" shall have the meaning set forth in Section 8.1.

          1.12  "THIRD PARTY" means any entity other than OCD or CORVAS or an
Affiliate of OCD or CORVAS.

          1.13  "UNIT" means a single IN VITRO diagnostic assay (i. e., used for
an individual determination).

          1.14  "VALID CLAIM" means a claim of an unexpired patent within Corvas
Patent Rights which has not been held unpatentable or invalid by a
non-appealable decision of a court or other appropriate body of competent
jurisdiction.

                                    ARTICLE 2
                   GRANT OF LICENSE AND ASSIGNMENT OF LICENSE

          2.1   GRANT OF LICENSE TO CORVAS PATENT RIGHTS. Subject to the terms
and conditions of this Agreement, CORVAS hereby grants to OCD a worldwide,
exclusive license, including the right to grant sublicenses, under the CORVAS
Patent Rights to develop, make, have made, use, offer for sale, sell and import
Multi-Test Automated PT Products for the Term.

                                       2
<PAGE>

          2.2   SUBLICENSES. OCD shall notify any sublicensee hereunder of all
rights and obligations of OCD under this Agreement which are sublicensed to such
sublicensee and shall notify CORVAS within 30 days of the grant of any
sublicense hereunder.

          2.3   ASSIGNMENT OF SCRIPPS LICENSE AGREEMENT. CORVAS hereby assigns
to OCD the Scripps License Agreement and all Of CORVAS' rights and obligations
thereunder. In partial consideration for such assignment, OCD hereby agrees that
it will not take any action which would impair its ability to assign the Scripps
License Agreement back to CORVAS pursuant to Section 8.3.

                                    ARTICLE 3
                                PRODUCT PAYMENTS

          3.1   LICENSE FEE. In partial consideration for the grant of the
license set forth in Section 2.1, OCD agrees to pay CORVAS a one-time,
non-refundable fee equal to [***] within 10 days after the Effective Date.

          3.2   ROYALTIES. During the Term, OCD shall pay to CORVAS a royalty
equal to [***] for each Unit of Multi-Test Automated PT Product sold or
transferred by OCD, its Affiliates or its sublicensees to any Third Party or
used by OCD, its Affiliates or its sublicensees for any Commercial Purpose.

                                    ARTICLE 4
                            PAYMENTS; RECORDS; AUDITS

          4.1   PAYMENT; REPORTS. Royalty payments and reports for the sale,
transfer or use, as the case may be, of Multi-Test Automated PT Product by OCD,
its Affiliates and sublicensees shall be calculated and reported for each
calendar quarter. All royalty payments due to CORVAS under this Agreement shall
be paid within 45 days of the end of each calendar quarter, unless otherwise
specifically provided herein. Each payment of royalties shall be accompanied by
a report of the number of Units of Multi-Test Automated PT Products sold,
transferred or used, as the case may be, including the royalties payable in U.S.
dollars, in sufficient detail to permit confirmation of the accuracy of the
royalty payment made.

          4.2   MANNER AND PLACE OF PAYMENT. All royalty payments due to CORVAS
under this Agreement shall be paid in U.S. dollars and shall be made by wire
transfer, unless otherwise specified by CORVAS.

          4.3   RECORDS AND AUDITS. During the Term and for a period of five
years thereafter, OCD shall keep complete and accurate records pertaining to the
sale or other disposition of Multi-Test Automated PT Products in sufficient
detail to permit CORVAS to confirm the accuracy of all payments due hereunder.
CORVAS shall have the right to cause an independent, certified public accountant
reasonably acceptable to OCD to audit such records to confirm sales of
Multi-Test Automated PT Products and royalty payments for the preceding year.
Such audits may be exercised during normal business hours once a year upon at
least 30 working days' prior written notice to OCD. CORVAS shall bear the full
cost of such audit unless such audit discloses an underpayment by more than 5%
of the amount of the royalties due under this Agreement. In such case, OCD shall
bear the full cost of such audit.

----------
***Confidential Treatment Requested.

                                       3
<PAGE>

          4.4   TAXES. All income taxes and taxes in lieu of income taxes levied
on account of the royalties accruing to CORVAS under this Agreement shall be
paid by CORVAS for its own account. If provision is made in law or regulation
for withholding, such tax shall be deducted from the royalty payment made by OCD
to the proper taxing authority and a receipt of payment of the tax secured and
promptly delivered to CORVAS. Each party agrees to assist the other party in
claiming exemption from or credit for such deductions or withholdings under any
double taxation or similar agreement or treaty from time to time in force.

                                    ARTICLE 5
                                 CONFIDENTIALITY

          5.1   NONDISCLOSURE. During the Term and for a period of five years
thereafter, each party will maintain all Confidential Information of the other
party as confidential and will not disclose any such Confidential Information to
any Third Party or use any Confidential Information for any purpose, except (a)
as expressly authorized by this Agreement, (b) as required by law or court
order, or (c) disclosure may be made to its Affiliates, employees, agents,
consultants and other representatives so long as such persons are under an
obligation of confidentiality no less stringent than set forth herein. Each
party may use such Confidential Information only to the extent required to
accomplish the purposes of this Agreement. Each party will use at least the same
standard of care as it uses to protect proprietary or confidential information
of its own to ensure that its Affiliates, employees, agents, consultants and
other representatives do not disclose or make any unauthorized use of the
Confidential Information of the other party. Each party will promptly notify the
other upon discovery of any unauthorized use or disclosure of the Confidential
Information of the other party.

          5.2   EXCEPTIONS. Confidential Information shall not include any
information which the receiving party can prove by competent evidence:

                (a) is now, or hereafter becomes, through no act or failure to
act on the part of the receiving party, generally known or available;

                (b) is lawfully known by the receiving party at the time of
receiving such information;

                (c) is hereafter furnished to the receiving party by a Third
Party, as a matter of right and without restriction on disclosure; or

                (d) is the subject of a written permission to disclose provided
by the disclosing party.

                                    ARTICLE 6
                          INTELLECTUAL PROPERTY RIGHTS

          6.1   APPLICATION, PROSECUTION AND MAINTENANCE OF CORVAS PATENT
RIGHTS. From and after the Effective Date, CORVAS shall be responsible for the
filing, prosecution and maintenance of all patent applications and patents
within the CORVAS Patent Rights. CORVAS shall keep OCD informed of significant
developments with regard to the filing, prosecution and maintenance of patent
applications and patents within the CORVAS Patent Rights. OCD shall cooperate
fully with CORVAS in the filing, prosecution and maintenance of patent
applications and patents within the CORVAS Patent Rights.

                                       4
<PAGE>

          6.2   REIMBURSEMENT OF PATENT EXPENSES. During the Term, OCD shall
reimburse CORVAS for all reasonable and documented costs and expenses incurred
by CORVAS in the filing, prosecution and maintenance of the CORVAS Patent Rights
within 30 days following receipt from CORVAS of copies of billing invoices for
such costs and expenses. Provided that OCD satisfies its reimbursement
obligations hereunder, CORVAS agrees that it shall diligently prosecute and
maintain all existing patents and patent applications within the CORVAS Patent
Rights, and further, that it shall file, prosecute and maintain any additional
patent applications and patents within the CORVAS Patent Rights as reasonably
directed in writing by OCD, in CORVAS' name and at OCD's sole expense. If OCD
subsequently informs CORVAS in writing that OCD no longer wishes to reimburse
CORVAS for expenses relating to any such patent application or patent in any
country, then CORVAS shall approach LifeScan, Inc. ("LIFESCAN") to assume such
obligation under that certain License Agreement dated as of July 22, 1998
between CORVAS and LIFESCAN to sell Single-Test PT Products. If LIFESCAN
likewise informs CORVAS in writing that it does not wish to reimburse CORVAS for
such patent expenses, effective upon receipt of such written communication, then
CORVAS shall be free, at its sole discretion and expense, and with no further
obligations to OCD under such CORVAS Patent Rights, to either abandon the
subject patent application or patent or to continue said prosecution and
maintenance. Any patent application or patent for which CORVAS shall assume the
responsibility for the cost of its prosecution and/or maintenance shall be
removed from the CORVAS Patent Rights and shall no longer be subject to any
right of OCD hereunder.

          6.3   INFRINGEMENT BY THIRD PARTIES. OCD and CORVAS shall promptly
notify the other in writing of any alleged or threatened infringement of any
patent included in the CORVAS Patent Rights of which they become aware. Both
parties shall use reasonable efforts in cooperating with each other to terminate
such infringement without litigation. OCD shall have the first right to bring
and control any action or proceeding with respect to any such infringement which
relates to any Multi-Test Automated PT Product, at its own expense and by
counsel of its own choice, and CORVAS shall have the right, at its own expense,
to be represented in any such action by counsel of its own choice. If OCD fails
to bring an action or proceeding with respect to any infringement of any CORVAS
Patent Rights, which relates to any Multi-Test Automated PT Product, within (a)
60 days following the notice of alleged infringement or (b) 10 days before the
time limit, if any, set forth in the appropriate laws and regulations for the
filing of such actions, whichever comes first, CORVAS, shall have the right to
bring and control any such action, at its own expense and by counsel of its own
choice, and OCD shall have the right, at its own expense, to be represented in
any such action by counsel of its own choice. CORVAS, or a party with which
CORVAS may contract or otherwise designate, shall have the right to bring and
control any action or proceeding with respect to any such infringement which
does not relate to any Multi-Test Automated PT Product, at its own expense and
by counsel of its own choice. In the event a party brings an infringement
action, the other party shall cooperate fully, including if required to bring
such action, the furnishing of a power of attorney. Neither party shall have the
right to settle any patent infringement litigation under this Section 6.3 in a
manner that diminishes the rights or interests of the other party or obligates
the other party to make any payment or take any action without the consent of
such other party. Except as otherwise agreed to by the parties as part of a cost
sharing arrangement, any recovery realized as a result of such litigation, after
reimbursement of any litigation expenses of OCD and CORVAS, shall belong to the
party who brought the action.

                                       5
<PAGE>

                                    ARTICLE 7
                    REPRESENTATIONS, WARRANTIES AND COVENANTS

          7.1   CORPORATE POWER. Each party hereby represents and warrants that
such party is duly organized and validly existing under the laws of the state of
its incorporation and has full corporate power and authority to enter into this
Agreement and to carry out the provisions hereof.

          7.2   DUE AUTHORIZATION. Each party hereby represents and warrants
that such party is duly authorized to execute and deliver this Agreement and to
perform its obligations hereunder, subject to the written consent of Scripps
Clinic and Research Foundation to the assignment of the Scripps License
Agreement from CORVAS to OCD pursuant to Section 2.3.

          7.3   BINDING AGREEMENT. Each party hereby represents and warrants
that this Agreement is a legal and valid obligation binding upon it and is
enforceable in accordance with its terms. The execution, delivery and
performance of this Agreement by such party does not conflict with any
agreement, instrument or understanding, oral or written, to which it is a party
or by which it may be bound, nor violate any law or regulation of any court,
governmental body or administrative or other agency having authority over it.

          7.4   OWNERSHIP OF CORVAS PATENT RIGHTS. CORVAS represents and
warrants that (a) CORVAS is the holder of all right, title and interest in and
to the CORVAS Patent Rights, (b) CORVAS has not granted any license under the
CORVAS Patent Rights and is under no obligation to grant any such license,
except to OCD and LIFESCAN, and (c) there are no outstanding liens,
encumbrances, agreements or understandings of any kind, either written, oral or
implied, regarding the CORVAS Patent Rights which are inconsistent or in
conflict with this Agreement.

          7.5   DISCLAIMER OF WARRANTIES. EXCEPT AS EXPRESSLY SET FORTH IN THIS
AGREEMENT, CORVAS DOES NOT MAKE ANY REPRESENTATION OR WARRANTY TO OCD OF ANY
KIND, EXPRESS OR IMPLIED, WITH RESPECT TO THE CORVAS PATENT RIGHTS OR THE PATENT
RIGHTS EMBRACED BY THE SCRIPPS LICENSE AGREEMENT, INCLUDING, WITHOUT LIMITATION,
ANY WARRANTY OF NONINFRINGEMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR
PURPOSE.

          7.6   LIMITATION OF LIABILITY. NEITHER CORVAS NOR OCD SHALL BE
ENTITLED TO RECOVER FROM THE OTHER PARTY ANY SPECIAL, INCIDENTAL, CONSEQUENTIAL
OR PUNITIVE DAMAGES IN CONNECTION WITH THE CORVAS PATENT RIGHTS, THE PATENT
RIGHTS EMBRACED BY THE SCRIPPS LICENSE AGREEMENT OR THE LICENSE GRANTED
HEREUNDER.

          7.7   INDEMNIFICATION. OCD hereby agrees to indemnify, save, defend
and hold harmless CORVAS and its officers, directors, employees, consultants and
agents from and against any and all suits, claims, actions demands, liabilities,
expenses and losses, including reasonable legal expenses and attorneys' fees
("Losses") arising directly or indirectly out of the practice of the license
granted hereunder, except to the extent such Losses result from the gross
negligence or the willful misconduct Of CORVAS. In the event CORVAS seeks
Indemnification under this Section 7.7, CORVAS shall inform OCD of a claim as
soon as reasonably practicable after CORVAS receives notice of the claim, shall
permit OCD to assume direction and control of the defense of the claim
(including the right to settle the claim solely for monetary consideration), and
shall cooperate as requested (at the expense of OCD) in the defense of the
claim.


                                       6
<PAGE>

                                    ARTICLE 8
                                TERM; TERMINATION

          8.1   TERM. This Agreement shall begin on the Effective Date and shall
end upon the expiration of the last to expire of the CORVAS Patent Rights (the
"Patent Expiration Date"), unless terminated earlier in accordance with the
terms of this Agreement (the "Term").

          8.2   TERMINATION.

                (a) Either party may terminate this Agreement prior to the
Patent Expiration Date upon or after the bankruptcy, insolvency, dissolution or
winding up of the other party (other than dissolution or winding up for the
purposes of reconstruction or amalgamation).

                (b) The non-breaching party may terminate this Agreement prior
to the Patent Expiration Date upon or after the breach of any material provision
of this Agreement by the other party if the breaching party has not cured such
breach within 60 days following written notice thereof by the non-breaching
party.

                (c) Either party may terminate this Agreement prior to the
Patent Expiration Date upon or after OCD, its Affiliates and sublicensees
discontinue the marketing, sale, distribution and use of all in-vitro diagnostic
assay products, which are not Single-Test PT Products, that incorporate [***]
following 60 days' written notice to the other party.

                (d) OCD may terminate this Agreement prior to the Patent
Expiration Date following written notice to CORVAS if (i) OCD has paid at least
[***] of cumulative royalties to CORVAS under this Agreement, or (ii) in the
event OCD has not paid at least [***] of cumulative royalties to CORVAS under
this Agreement, OCD pays CORVAS the difference between [***] and the
cumulative royalties actually paid to CORVAS to date.

          8.3   EFFECT OF EXPIRATION OR TERMINATION.

                (a) Upon termination of this Agreement by either party pursuant
to Section 8.2(a), all rights to the CORVAS Patent Rights under this Agreement
shall revert to CORVAS, all royalty obligations under Section 3.2 shall
terminate, and OCD shall, in its sole discretion, either (i) assign the Scripps
License Agreement back to CORVAS, or (ii) sublicense all rights granted to
CORVAS under the Scripps License Agreement necessary to develop, make, have
made, use, offer for sale, sell and import Multi-Test Automated PT Products back
to CORVAS on the same terms and conditions as in the Scripps License Agreement.

                (b) Upon termination of this Agreement by either party pursuant
to Section 8.2(c), by CORVAS pursuant to Section 8.2(b) or by OCD pursuant to
Section 8.2(d), all rights to the CORVAS Patent Rights shall revert to CORVAS,
any and all sublicenses granted hereunder by OCD shall remain in effect, but
shall be assigned to CORVAS, and OCD shall, in its sole discretion, except for
termination by CORVAS pursuant to Section 8.2(b) in which case it shall be in
CORVAS' sole discretion to, either (i) assign the Scripps License Agreement back
to CORVAS, or (ii) sublicense all rights granted to CORVAS under the Scripps
License Agreement necessary to develop, make, have made, use, offer for sale,
sell and import Multi-Test Automated PT Products back to CORVAS on the same
terms and conditions as in the Scripps License Agreement.

----------
***Confidential Treatment Requested.

                                       7
<PAGE>

                (c) Upon termination of this Agreement by OCD pursuant to
Section 8.2(b), the license granted under Section 2.1 shall remain in effect so
long as OCD does not breach its obligations to CORVAS under this Agreement, and
all royalty obligations under Section 3.2 shall terminate.

                (d) Upon termination of this Agreement for any reason other than
by CORVAS pursuant to Section 8.2, OCD shall have the right for a period of 18
months following the date of termination to finish any work-in-process and to
dispose of any Multi-Test Automated PT Products in its possession or control;
PROVIDED, HOWEVER, OCD shall make all royalty payments to CORVAS relating to
such Multi-Test Automated PT Products as required under Section 3.2.

                (e) Expiration or termination of this Agreement shall not
relieve the parties of any obligation accruing prior to such expiration or
termination. The provisions of Sections 4.3, 7.5, 7.6, 7.7 and 8.3 and Articles
1, 5 and 9 shall survive termination or expiration of this Agreement.

                (f) Termination of this Agreement by a party pursuant to Section
8.2 shall not confer upon OCD any right to practice within the CORVAS Patent
Rights in the absence of a license to the CORVAS Patent Rights or other such
express authorization from CORVAS.

                                    ARTICLE 9
                                  MISCELLANEOUS

          9.1   FORCE MAJEURE. Neither party shall be held liable or responsible
to the other party nor be deemed to have defaulted under or breached this
Agreement for failure or delay in fulfilling or performing any term of this
Agreement when such failure or delay is caused by or results from causes beyond
the reasonable control of the affected party, including, but not limited to,
fire, floods, embargoes, war, acts of war (whether war be declared or not),
insurrections, riots, civil commotions, strikes, lockouts or other labor
disturbances, acts of God or acts, omissions or delays in acting by any
governmental authority or the other party.

          9.2   ASSIGNMENT.

                (a) Except as expressly provided hereunder, neither this
Agreement nor any rights or obligations hereunder may be assigned or otherwise
transferred by either party without the prior written consent of the other party
(which consent shall not be unreasonably withheld); PROVIDED, HOWEVER, that
either party may assign this Agreement and its rights and obligations hereunder
without the consent of the other party (i) in connection with the transfer or
sale of all or substantially all of the assets of such party to which this
Agreement pertains (for the avoidance of doubt, such assets shall consist of the
tangible and intangible property related to Multi-Test Automated PT Products for
monitoring or evaluating bleeding and/or clotting processes), (ii) in the event
of a merger or reorganization of such party with or into another party, or (iii)
to any Affiliate. Notwithstanding the foregoing, any such assignment to an
Affiliate shall not relieve the assigning party of its responsibilities for
performance of its obligations under this Agreement.

                (b) The rights and obligations of the parties under this
Agreement shall be binding upon and inure to the benefit of the successors and
permitted assigns of the parties. Any assignment not in accordance with this
Agreement shall be void.

                                       8
<PAGE>

          9.3   PUBLICITY. The parties agree that neither party will originate
any press release or other public announcement, written or oral, or otherwise
make any disclosure relating to the existence or terms of or performance under
this Agreement without the prior written approval of the other party, except as
may otherwise be required by law, including compliance with securities laws (in
which case the disclosing party shall still consult with the other party prior
to such disclosure).

          9.4   GOVERNING LAW AND ARBITRATION. All matters affecting the
interpretation, validity and performance of this Agreement shall be governed by
the laws of the State of New Jersey. Any and all disputes between the parties
relating in any way to the execution of this Agreement and/or the validity,
construction, meaning, enforceability, or performance of this Agreement or any
of its provisions, or the intent of the parties in entering into this Agreement,
or any dispute relating to patent validity or infringement arising under this
Agreement, shall be settled by arbitration. Such arbitration shall be conducted
in San Diego, California if initiated by OCD, or in New Brunswick, New Jersey if
initiated by CORVAS, in accordance with the rules then pertaining to the
American Arbitration Association with a panel of three arbitrators. The
arbitrators shall be selected from the National Panel of Arbitrators of the
American Arbitration Association (the "AAA"). Each party shall select one
arbitrator and the two selected arbitrators shall select the third arbitrator.
If the two selected arbitrators cannot agree on a third arbitrator then the AAA
shall select the third arbitrator from the National Panel of Arbitrators.
Reasonable discovery as determined by the arbitrators shall apply to the
arbitration proceeding. The law of the State of New Jersey shall apply to the
arbitration proceedings. Judgment upon the award rendered by the arbitrators may
be entered in any court having jurisdiction thereof.

          9.5   WAIVER. Except as specifically provided for herein, the waiver
from time to time by either of the parties of any of their rights or their
failure to exercise any remedy shall not operate or be construed as a continuing
waiver of the same rights or remedies or of any other of such party's rights or
remedies provided in this Agreement.

          9.6   SEVERABILITY. If any term, covenant or condition of this
Agreement or the application thereof to any party or circumstance shall, to any
extent, be held to be invalid or unenforceable, then (a) the remainder of this
Agreement, or the application of such term, covenant or condition to parties or
circumstances other than those as to which it is held invalid or unenforceable,
shall not be affected thereby and each term, covenant or condition of this
Agreement shall be valid and be enforced to the fullest extent permitted by law;
and (b) the parties hereto covenant and agree to renegotiate any such term,
covenant or application thereof in good faith to provide a reasonably acceptable
alternative to the term, covenant or condition of this Agreement or the
application thereof that is invalid or unenforceable, it being the intent of the
parties that the basic purposes of this Agreement are to be effectuated.

          9.7   TERMINATION OF LICENSE AGREEMENT. CORVAS and OCD hereby agree
that, as of the Effective Date, the License Agreement shall terminate and all
rights and obligations thereunder shall be extinguished.

          9.8   ENTIRE AGREEMENT; AMENDMENT. This Agreement sets forth all of
the covenants, promises, agreements, warranties, representations, conditions and
understandings between the parties hereto with respect to the subject matter of
this Agreement, and supersedes and terminates all prior agreements and
understanding between the parties with respect to the subject matter of this
Agreement, including the License Agreement. There are no covenants, promises,
agreements, warranties, representations, conditions or understandings with
respect to the subject matter hereof, either oral or written, between the
parties other than as set forth herein. No subsequent alteration, amendment,
change or addition to this Agreement shall be binding upon the parties hereto
unless reduced to writing and signed by the respective authorized officers of
the parties.


                                       9
<PAGE>

          9.9   RELATIONSHIP OF THE PARTIES. It is expressly agreed that CORVAS
and OCD shall be independent contractors and that the relationship between the
two parties shall not constitute a partnership, joint venture or agency of any
kind. Neither party shall have the authority to make any statements,
representations or commitments of any kind, or to take any action, which shall
be binding on the other, without the prior written authorization of the other
party.

          9.10  NOTICES. Any notices or communications provided for in this
Agreement to be made by either of the parties to the other shall be in writing
and delivered personally or sent by United States mail, registered or certified,
postage paid, by overnight delivery service such as FedEx or UPS or by
facsimile, with confirmation of receipt, addressed as follows:

 If to CORVAS:                               CORVAS INTERNATIONAL, INC.
                                             3030 Science Park Road
                                             San Diego, CA 92121
                                             Attn: Corporate Secretary
                                             Phone No. (619) 455-9800
                                             Fax No. ( 619) 455-7895

 If to OCD or LIFESCAN:                      JOHNSON & JOHNSON
                                             One Johnson & Johnson Plaza
                                             New Brunswick, NJ 08933-7003
                                             Attn: Gerard Vaillant
                                             Company Group Chairman
                                             Phone No. (908) 218-8601
                                             Fax No. ( 908) 704-3905

          Either party may by like notice specify or change an address to which
notices and communications shall thereafter be sent. Notices sent by facsimile
shall be effective upon confirmation of receipt, notices sent by mail or
overnight delivery service shall be effective upon receipt, and notices given
personally shall be effective when delivered.

          9.11  HEADINGS. The captions contained in this Agreement are not a
part of this Agreement, but are merely guides or labels to assist in locating
and reading the several Articles hereof.

          9.12   COUNTERPARTS. This Agreement may be executed in two or more
Counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument.

                                       10
<PAGE>

          In Witness Whereof, the parties have executed this Agreement as of the
date first set forth above.

 CORVAS INTERNATIONAL, INC.                     ORTHO-CLINICAL DIAGNOSTICS, INC.

 /s/ RANDALL E. WOODS  11-6-98                  /s/ GERARD VAILLANT
 -----------------------------                  -------------------
 Randall E. Woods                               Gerard Vaillant
 President and Chief Executive Officer          Chairman












                                License Agreement

                                       11
<PAGE>

<TABLE>
<CAPTION>

                                                           EXHIBIT A
                                                           ---------
                                                      CORVAS PATENT RIGHTS
                                                      --------------------

-----------------------------------------------------------------------------------------------------------------------------------
Docket No.        Title                                                   Serial Number        Filing Date
Appl. Type        (Inventor)                                              PATENT NUMBER        (Issue Date)        Status
-----------------------------------------------------------------------------------------------------------------------------------
<S>               <C>                                                     <C>                  <C>                 <C>
[***]             [***]                                                   07/612,118           [***]               [***]
-----------------------------------------------------------------------------------------------------------------------------------
[***]             [***]                                                   08/126,668           [***]               [***]
-----------------------------------------------------------------------------------------------------------------------------------
[***]             [***]                                                   08/427,683           [***]               [***]
-----------------------------------------------------------------------------------------------------------------------------------
195/185           Tissue factor based prothrombin time reagent(Brown)     07/784,326           10-29-91            ISSUED PATENT
CIP                                                                       US5,314,695          (5-24-94)
-----------------------------------------------------------------------------------------------------------------------------------
195/185PCT        [***]                                                   PCT                  [***]               [***]
                                                                          US91/08174
-----------------------------------------------------------------------------------------------------------------------------------
[***]             [***]                                                   EPO                  [***]               [***]
                                                                          92901065
-----------------------------------------------------------------------------------------------------------------------------------
[***]             [***]                                                   JPN                  [***]               [***]
                                                                          501271/1992
-----------------------------------------------------------------------------------------------------------------------------------
[***]             [***]                                                   CAN                  [***]               [***]
                                                                          2096109
-----------------------------------------------------------------------------------------------------------------------------------
-----------------------------------------------------------------------------------------------------------------------------------
</TABLE>

----------
***Confidential Treatment Requested.

                                       12
<PAGE>

<TABLE>
<CAPTION>

-----------------------------------------------------------------------------------------------------------------------------------
Docket No.        Title                                                   Serial Number        Filing Date
Appl. Type        (Inventor)                                              PATENT NUMBER        (Issue Date)        Status
-----------------------------------------------------------------------------------------------------------------------------------
<S>               <C>                                                     <C>                  <C>                 <C>
[***]             [***]                                                   AUS                  [***]               [***]
                                                                          90907/91
-----------------------------------------------------------------------------------------------------------------------------------
[***]             [***]                                                   AUS                  [***]               [***]
                                                                          44489/96
-----------------------------------------------------------------------------------------------------------------------------------
[***]             [***]                                                   FIN                  [***]               [***]
                                                                          932148
-----------------------------------------------------------------------------------------------------------------------------------
[***]             [***]                                                   IRE                  [***]               [***]

-----------------------------------------------------------------------------------------------------------------------------------
[***]             [***]                                                   KOR                  [***]               [***]
                                                                          701454/93
-----------------------------------------------------------------------------------------------------------------------------------
[***]             [***]                                                   MEX                  [***]               [***]

-----------------------------------------------------------------------------------------------------------------------------------
195/185NZ*        Tissue factor based prothrombin time reagent(Brown)     NZ240577             11-13-91            ISSUED PATENT
                                                                          (NZ240577)           (11-5-96)
-----------------------------------------------------------------------------------------------------------------------------------
195/185-D1NZ      Tissue factor based prothrombin time reagent(Brown)     NZ264,556              -  -94            ISSUED PATENT
DIV                                                                       (NZ264,556)          (11-6-96)
-----------------------------------------------------------------------------------------------------------------------------------
[***]             [***]                                                   NOR                  [***]               [***]
                                                                          931708
-----------------------------------------------------------------------------------------------------------------------------------
[***]             [***]                                                   POR                  [***]               [***]
                                                                          99499
-----------------------------------------------------------------------------------------------------------------------------------
</TABLE>

*Indicates application was filed directly in national patent office; not through
 PCT.

----------
*** Confidential Treatment Requested.

                                       13